MedTrace Logo

A Study of AK130 in Patients With Advanced Malignant Tumors

NCT05653284 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-08-13

No results posted yet for this study

Summary

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

AK130

IV infusion, specified dose on specified days.

Sponsors & Collaborators

Principal Investigators

  • Jinming Yu · The Cancer Hospital Affiliated to Shandong First Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-09
Primary Completion
2023-12-12
Completion
2024-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05653284 on ClinicalTrials.gov